Markus Grompe

USPTO Granted Patents = 11 (Patent Applications = 8)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 13(Granted Patents)

Company Filing History:

10 out of 504

Oregon Health & Science University

patents

3 out of 1,209

Dana-farber-cancer Institute Inc.

patents

2 out of 1,746

Mayo Foundation for Medical Education and Research

patents

4. 1 out of 5,307

Leland Stanford Junior University

patents

where one patent can have more than one assignee

Years Active: 2000-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11421218 - Methods for enhancing the efficiency of gene editing (2022-08-23),

2. 10738310 - Treating cancer deficient in FANCA, FANCD2, FANCE, or FANCG with an ATM inhibitor (2020-08-11),

3. 9566315 - Normalization of the enterohepatic circulation in animals with a chimeric humanized liver (2017-02-14),

4. 9485971 - Fumarylacetoacetate hydrolase (Fah)-deficient pigs and uses thereof (2016-11-08),

5. 9354224 - Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof (2016-05-31),

6. 9000257 - Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof (2015-04-07),

7. 8569573 - Method of expanding human hepatocytes in vivo (2013-10-29),

8. 8247186 - Monoclonal antibodies and their use (2012-08-21),

9. 8097428 - Monoclonal antibodies and their use (2012-01-17),

10. 7981628 - Monoclonal antibodies and their use (2011-07-19),

11. 6132708 - Liver regeneration using pancreas cells (2000-10-17),

Title: Innovations and Contributions of Inventor Markus Grompe

Introduction

Markus Grompe is a prominent inventor based in Portland, OR (US), known for his significant contributions to the field of gene editing and cancer treatment. With a total of 11 patents to his name, Grompe has made remarkable strides in enhancing the efficiency of genetic modifications and developing therapeutic methods for cancer.

Latest Patents

Among his latest patents, Grompe has developed methods for enhancing the efficiency of gene editing. This invention provides innovative techniques aimed at increasing the effectiveness of genome editing processes. Additionally, he has created compositions and methods for treating cancer that is deficient in FANCA, FANCD2, FANCE, or FANCG, utilizing an ATM inhibitor. This invention also includes methods for accessing and monitoring the responsiveness of cancer cells to therapeutic compounds.

Career Highlights

Throughout his career, Markus Grompe has worked with esteemed institutions such as Oregon Health & Science University and Dana-Farber Cancer Institute Inc. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of Grompe's notable coworkers include Philip R. Streeter and Craig Dorrell. Their collaborative efforts have further advanced the research and development of innovative solutions in gene therapy and cancer treatment.

Conclusion

Markus Grompe's contributions to the fields of gene editing and cancer treatment exemplify the impact of innovative thinking in science and medicine. His patents and collaborations continue to pave the way for future advancements in these critical areas.

This text is generated by artificial intelligence and may not be accurate.